Thalidomide-linker 2

Background Introduction

Thalidomide-linker 2 is a specialized E3 ligase ligand-linker conjugate designed for use in targeted protein degradation research, specifically within the context of PROTAC (Proteolysis Targeting Chimera) technology. As a derivative of thalidomide, Thalidomide-linker 2 enables efficient recruitment of the cereblon (CRBN) E3 ubiquitin ligase, which plays a critical role in mediating ubiquitination and proteasomal degradation of target proteins. This product is structurally optimized with a functionalized linker, facilitating the rational design of bifunctional PROTAC molecules.

Mechanism

Thalidomide-linker 2 operates by serving as the E3 ligase-recruiting moiety in the molecular architecture of PROTACs. The thalidomide portion binds selectively to the CRBN E3 ligase, while the chemical linker provides a reactive handle for conjugation to a ligand specific for a protein of interest. Once incorporated into a PROTAC molecule, Thalidomide-linker 2 orchestrates the spatial proximity between the E3 ligase and the designated target protein. This induced proximity promotes the ubiquitination of the target protein by CRBN, marking it for subsequent recognition and degradation by the cellular proteasome system.

Applications

Thalidomide-linker 2 is widely used in the development of next-generation targeted protein degradation therapeutics, chemical biology research, and drug discovery pipelines. Its key applications include: (1) Synthesis of PROTACs targeting a diverse array of disease-relevant proteins, including kinases, transcription factors, and epigenetic regulators; (2) Mechanistic studies investigating the efficiency and selectivity of CRBN-mediated protein degradation; and (3) Exploration of structure-activity relationships (SAR) to enhance the pharmacological properties of PROTAC molecules. Employing Thalidomide-linker 2 enables researchers to accelerate the generation of effective and specific protein degraders, driving innovation in personalized medicine and biotechnology.

The Thalidomide-linker 2 is an E3 Ligase Ligand-Linker Conjugate designed for use in PROTACs, facilitating targeted protein degradation by bridging the E3 ligase and the target protein. This conjugate enhances selectivity and efficacy in protein degradation applications, providing a robust platform for advancing research in targeted therapeutics. The following provides a detailed description of this molecule.

Linker: The linker in Thalidomide-linker 2 is a medium-length, flexible alkyl chain that ensures optimal spatial arrangement between the ligand and the target protein. Its flexibility aids in accommodating various protein conformations, while its non-cleavable nature ensures stability during the degradation process.

Ligand: The ligand is a derivative of thalidomide, known for its ability to recruit the CRBN E3 ligase. Its structural characteristics include a glutarimide moiety, which is critical for specific binding to the E3 ligase, thus enhancing the efficacy of the PROTAC.

Reactive Site: The reactive site in this molecule is designed to couple with the target protein ligand via amide bond formation. Recommended reaction types include amide coupling reactions, which provide robust and stable linkages essential for effective protein degradation.

Recommended Target Protein Ligand: A suitable warhead for this conjugate is a small molecule inhibitor with a nucleophilic functional group, such as an amine or hydroxyl. This compatibility ensures efficient covalent attachment to the linker, facilitating the degradation of the target protein. This approach is advantageous for studying protein function and validating potential therapeutic targets in experimental settings.